NCT00058422View on ClinicalTrials.gov

Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 10, 2003

Primary Completion Date

November 14, 2019

Study Completion Date

November 14, 2019

Conditions

Lymphoma

Interventions

BIOLOGICAL

darbepoetin alfa

BIOLOGICAL

filgrastim

BIOLOGICAL

rituximab

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

prednisone

DRUG

vincristine sulfate

RADIATION

indium In 111 ibritumomab tiuxetan

RADIATION

yttrium Y 90 ibritumomab tiuxetan

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00058422 - Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma | Biotech Hunter | Biotech Hunter